Replies to post #173798 on Biotech Values

[fung_derf]

I see GILD as a buy under $75

[DewDiligence]

GILD—Elliot Favus offers some reasons to sell the stock, including…a shareholder base which has become too generalized and don't understand hepatitis-C.

That’s retarded, IMO. (I don’t care if it’s non-PC to use the word.) There are reasons for not owning GILD at the current valuation that do make sense, but that’s not one of them.